Skip to main content

Genaissance Licenses HAP Data, Informatics to AstraZeneca

NEW YORK, Dec. 11 - Genaissance Pharmaceuticals has given AstraZeneca access to specific HAP markers and its DecoGen informatics platform to help the pharmaceutical firm bolster its drug-discovery efforts, Genaissance said on Tuesday.

 

Financial or research details of the deal, the third of its kind that Genaissance has struck with a major pharmaceutical company, were not disclosed.

 

Genaissance, of New Haven, Conn., has a cache of almost 100,000 haplotypes from more than 5,400 genes and said it intends to discover haplotypes for all human genes.

 

"Pharmacogenomics has an expanding role to play in drug discovery and development," John Stageman, AstraZeneca's vice president of enabling science and technology, said in a statement. "AstraZeneca looks forward to using Genaissance's advanced HAP Technology platform and evaluating its potential to accelerate our internal efforts."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.